1. Search Result
Search Result
Results for "

M-2

" in MedChemExpress (MCE) Product Catalog:

946

Inhibitors & Agonists

1

Screening Libraries

8

Fluorescent Dye

16

Biochemical Assay Reagents

13

Peptides

12

Inhibitory Antibodies

120

Natural
Products

10

Recombinant Proteins

52

Isotope-Labeled Compounds

16

Antibodies

7

Click Chemistry

8

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18657
    TEPP-46
    50+ Cited Publications

    ML-265

    Pyruvate Kinase Cancer
    TEPP-46 (ML-265) is a potent and selective pyruvate kinase M2 (PKM2) activator with an AC50 of 92 nM, showing little or no effect on PKM1, PKL and PKR [2] .
    TEPP-46
  • HY-103617
    PKM2-IN-1
    25+ Cited Publications

    Pyruvate Kinase Cancer
    PKM2-IN-1 (compound 3k) is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95 μM .
    PKM2-IN-1
  • HY-10082
    Triapine
    5+ Cited Publications

    3-AP; PAN-811; OCX191

    DNA/RNA Synthesis Cancer
    Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.
    Triapine
  • HY-B0406A
    Bethanechol chloride
    2 Publications Verification

    Carbamyl-β-methylcholine chloride

    mAChR Neurological Disease Cancer
    Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol chloride
  • HY-A0034
    Solifenacin
    3 Publications Verification

    YM905 free base

    mAChR Neurological Disease Cancer
    Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin
  • HY-B0461

    mAChR Neurological Disease
    Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors [2].
    Trospium chloride
  • HY-B2116
    Osalmid
    2 Publications Verification

    Oxaphenamide; 4'-Hydroxysalicylanilide

    Environmental Pollutants HBV Infection Cancer
    Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
    Osalmid
  • HY-A0002
    Solifenacin Succinate
    3 Publications Verification

    YM905

    mAChR Neurological Disease Cancer
    Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin Succinate
  • HY-101381
    Otenzepad
    2 Publications Verification

    AF-DX 116

    mAChR Neurological Disease Metabolic Disease
    Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively .
    Otenzepad
  • HY-B0338A

    Influenza Virus Autophagy Infection
    Rimantadine hydrochloride (Flumadine hydrochloride) is an orally active inhibitor for M2 protein, that blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity .
    Rimantadine hydrochloride
  • HY-128669
    Abemaciclib metabolite M2
    2 Publications Verification

    LSN2839567

    CDK Drug Metabolite Cancer
    Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity [2].
    Abemaciclib metabolite M2
  • HY-15885

    mAChR Neurological Disease
    LY2119620 is a high-affinity muscarinic M2/M4 receptor agonist.
    LY2119620
  • HY-B1076
    Medrysone
    1 Publications Verification

    HMS; 6α-Methyl-11β-hydroxyprogesterone

    VEGFR CCR STAT Neurological Disease
    Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .
    Medrysone
  • HY-112358

    CDK Neurological Disease Cancer
    GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities [2] .
    GW8510
  • HY-N3963

    (+)-Gomisin M2

    HIV Infection Neurological Disease Inflammation/Immunology Cancer
    Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-HIV activity (EC50 of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer’s disease research [2].
    Gomisin M2
  • HY-101239

    mAChR Neurological Disease
    Oxotremorine sesquifumarate is a mAChR agonist that mainly activates M2 receptors. Oxotremorine sesquifumarate can be used for neurological research [2].
    Oxotremorine sesquifumarate
  • HY-100341

    Checkpoint Kinase (Chk) Others
    M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC) .
    M2I-1
  • HY-I0678

    Drug Metabolite PDGFR Cancer
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (M2)
  • HY-I0230
    Solifenacin hydrochloride
    3 Publications Verification

    YM905 hydrochloride

    mAChR Neurological Disease Cancer
    Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin hydrochloride
  • HY-147368

    Pyruvate Kinase Cancer
    PKM2 activator 2 (compound 28) is a pyruvate kinase M2 (PKM2) activitor with an AC50 value of 66 nM. PKM2 activator 2 can restore normal glycolytic metabolism in cells .
    PKM2 activator 2
  • HY-B0402S

    1-Adamantanamine-d15; 1-Aminoadamantane-d15

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Infection Neurological Disease Cancer
    Amantadine-d15 is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells. Amantadine is an antiparkinsonian agent [2].
    Amantadine-d15
  • HY-P11107

    Apoptosis TNF Receptor Inflammation/Immunology Cancer
    RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) [2].
    RP-832c
  • HY-14825A

    SVT-40776 D-tartrate

    mAChR Neurological Disease
    Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.
    Tarafenacin D-tartrate
  • HY-134061

    Apoptosis Mitosis Cancer
    Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .
    Arecaidine propargyl ester hydrobromide
  • HY-128669S

    LSN2839567-d6

    CDK Cancer
    Abemaciclib metabolite M2-d6 is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity [2].
    Abemaciclib metabolite M2-d6
  • HY-P1783A
    M2e, human TFA
    1 Publications Verification

    Influenza Virus Infection
    M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A .
    M2e, human TFA
  • HY-E70073

    Sialidase isoenzyme M2; AuSialidase M2

    Biochemical Assay Reagents Others
    Ganglioside sialidase (AuSialidase M2) from Arthrobacter ureafaciens. Ganglioside sialidase is a highly specific N-acetylneuraminidase. Ganglioside sialidase can hydrolyze the internal sialic acid of GM1 under optimal condition with sodium cholate .
    Ganglioside sialidase (AuSialidase M2)
  • HY-172273A

    Liposome Cancer
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY
  • HY-101586

    Lu 25-109

    mAChR Neurological Disease
    Alvameline (Lu25-109) is a partial M1 agonist and M2/M3 antagonist.
    Alvameline
  • HY-162897

    mAChR Cardiovascular Disease
    BAY-2413555 is an orally active muscarinic acetylcholine receptor M2 modulator that protects the heart and improve cardiac function. BAY-2413555 is promising for research of heart failure .
    BAY-2413555
  • HY-128769

    CDK Cancer
    M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC50 value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC50 values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research .
    M2N12
  • HY-I0678S

    PDGFR Drug Metabolite Cancer
    Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2 . Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively [2].
    Regorafénib N-oxyde-d3 (M2)
  • HY-119874

    Pyruvate Kinase Inflammation/Immunology Cancer
    Alkannin is a potent and specific inhibitor of tumor-specific pyruvate kinase-M2 (PKM2). Alkannin does not inhibit PKM1 and pyruvate kinase-L (PKL). Alkannin acts as a potential anticancer agent .
    Alkannin
  • HY-B0406

    Carbamyl-β-methylcholine

    mAChR Neurological Disease Cancer
    Bethanechol (Carbamyl-β-methylcholine), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol
  • HY-101671

    M-2

    MMP Drug Metabolite Inflammation/Immunology
    S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
    S-methyl-KE-298
  • HY-172273

    Liposome Cancer
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY
  • HY-163642

    Others Cancer
    TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .
    TNF-α agonistic 1
  • HY-162031

    JAK Metabolic Disease
    MMT3-72-M2 is an MMT3-72 metabolite. MMT3-72-M2 is a selective JAK1 inhibitor. MMT3-72-M2 inhibits JAK1, JAK2, TYK2, and JAK3 with IC50 values of 10.8 nM, 26.3 nM, 91.6 nM, 328.7 nM, respectlly .
    MMT3-72-M2
  • HY-172273C

    Liposome Cancer
    DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG3400-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
    DSPE-PEG3400-M2pep
  • HY-I0678S1

    Drug Metabolite Cancer
    Regorafénib N-oxyde (M2)- 13C,d3 is the 13C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (M2)-13C,d3
  • HY-N14824

    Fungal Infection
    Neoenactin M2 has strong anti-yeastlike and filamentous fungal effects .
    Neoenactin M2
  • HY-75867

    Influenza Virus Infection
    M2 ion channel blocker-1 is capable of inhibiting and blocking the activity of M2 ion channel;Antiviral agent.
    M2 ion channel blocker-1
  • HY-130431

    Parasite Infection
    Vinclozolin M2 is an active metabolite of vinclozolin. It is formed from vinclozolin by successive esterase activity and decarboxylation of vinclozolin in C. elegans and by decarboxylation in human liver microsomes. Vinclozolin M2 is an antagonist of the mineralocorticoid receptor (IC50=1,400 nM) and androgen receptor (IC50=0.17 nM) in reporter assays using MCF-7 cells.
    Vinclozolin M2
  • HY-178672

    Anti-Reverse cap analog; m2 7,3′O GpppG

    DNA/RNA Synthesis Cancer
    ARCA (Anti-Reverse cap analog) is a 5′- cap analogue. ARCA caps mRNA. ARCA can be used in protein expression studies .
    ARCA
  • HY-107755

    4,4-Pentamethylenepiperidine hydrochloride

    Influenza Virus Infection
    3-Azaspiro[5.5]undecane (4,4-Pentamethylenepiperidine) hydrochloride is an inhibitor targeting the WT influenza A virus M2 (A/M2), with an IC50 of 1 μM .
    3-Azaspiro[5.5]undecane hydrochloride
  • HY-128669R

    LSN2839567 (Standard)

    Reference Standards CDK Drug Metabolite Cancer
    Abemaciclib metabolite M2 (Standard) is the analytical standard of Abemaciclib metabolite M2. This product is intended for research and analytical applications. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity[1][2].
    Abemaciclib metabolite M2 (Standard)
  • HY-N3248

    Momordicacoside G

    Endogenous Metabolite Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology Cancer
    Momordicoside G (Momordicacoside G) is an orally active cucurbitane-type triterpene glycoside. Momordicoside G selectively induces apoptosis of M1-like macrophages, without affecting M2-like macrophages. Momordicoside G reduces intracellular ROS levels and promotes autophagy. Momordicoside G also has anticancer activity, inhibiting the growth of cancer cell lines. Momordicoside G stimulates M2-associated lung injury repair and prevents inflammatory lung cancer injury .
    Momordicoside G
  • HY-101671R

    M-2 (Standard)

    Reference Standards MMP Drug Metabolite Inflammation/Immunology
    S-methyl-KE-298 (Standard) is the analytical standard of S-methyl-KE-298. This product is intended for research and analytical applications. S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
    S-methyl-KE-298 (Standard)
  • HY-154749S

    Isotope-Labeled Compounds Others
    Repaglinide M2-d5 is deuterated labeled Repaglinide M2.
    Repaglinide M2-d5
  • HY-179217

    JNK Apoptosis Cancer
    GSTP1/M2-IN-1 is a GSTP1/GSTM2 inhibitor(IC50 = 1.56 μM/0.09 μM). GSTP1/M2-IN-1 can activate the JNK pathway and induce cell apoptosis. GSTP1/M2-IN-1 can be used for the study of breast cancer and pancreatic cancer .
    GSTP1/M2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: